10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG) from its SEC filings: 2025 revenue $642.8 million (+5% vs the year before), net margin -7%, free cash flow $130.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Laboratory Analytical Instruments |
| Revenue (2025) | $642.8 million |
| Revenue growth | +5% |
| Net income | -$43.5 million |
| Net margin | -6.8% |
| Free cash flow | $130.1 million |
| Diluted EPS | $-0.35 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -13% |
| Cash | $344.1 million |
| Long-term debt | $0 |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.